Sectors

We are pleased to be included on TIME’s World’s Most Impactful Companies 2026 list, recognising organisations creating positive impact across society, health, the environment and knowledge. The ranking is based on an in...

ADCs, radiopharmaceuticals and next-generation cell therapies are creating new possibilities in oncology, alongside increasingly specialised clinical, operational and regulatory requirements. Connect with ICON at #ESMO26...

How do you identify the right patients when no fit-for-purpose assay exists? Join our session at Biomarkers & Precision Medicine Europe on 14 October at 11:20 to discover practical approaches to regulated biomarker and g...

As AI adoption accelerates across clinical development, the question is no longer whether to use AI in medical writing, but how to use it effectively. For complex regulatory documents such as clinical study reports (CSR...

Navigating an increasingly complex regulatory environment requires the right combination of global expertise, local knowledge and practical delivery. At next week’s TOPRA Symposium, regulatory professionals from across ...

ICON has been named a Leader in the Everest Group Life Sciences Regulatory Affairs Services PEAK Matrix® Assessment 2026. The assessment evaluates regulatory affairs service providers across Market Impact, Vision and Ca...

Quality is fundamental to how ICON supports clinical research. ICON maintains a global quality management system designed to support compliance, risk management and continuous improvement. In 2025, our teams conducted 9...

Nearly 1 in 7 people in the world live with a mental disorder. This World Mental Health Day, we’re highlighting the importance of clinical research in addressing unmet needs in mental health. Over the past 5 years, has c...

Women are disproportionately affected by gonorrhoea, frequently remaining asymptomatic until severe complications like pelvic inflammatory disease or infertility arise. Traditional preclinical models fall short of reprod...

Managing post-marketing pharmacovigilance across global markets presents significant challenges, from meeting local regulatory requirements to ensuring timely safety reporting and oversight. In this article, Quintin van ...

As regulatory expectations for biosimilars continue to evolve, bioanalytical strategy is becoming increasingly important in demonstrating biosimilarity. In this BioProcess International article, authors Kimberly Salgado...

How can sponsors generate meaningful clinical insights earlier in neurodegenerative disease development? Join ICON specialists Paula Kopschina Feltes and Matthias Mohse as they explore innovative first-in-human study des...